Intercept Pharmaceuticals (NASDAQ:ICPT) had its price objective reduced by investment analysts at Stifel Nicolaus from $100.00 to $51.00 in a report issued on Monday, The Fly reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price points to a potential upside of 6.45% from the company’s current price.
Several other research analysts have also issued reports on the stock. Wedbush restated a “buy” rating and issued a $257.00 price target on shares of Intercept Pharmaceuticals in a research report on Thursday, May 14th. BMO Capital Markets cut shares of Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $107.00 to $52.00 in a research report on Monday. ValuEngine upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, May 3rd. Citigroup cut shares of Intercept Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $110.00 price objective on the stock. in a research report on Tuesday, May 12th. Finally, BidaskClub upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Eighteen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Intercept Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $81.48.
Intercept Pharmaceuticals stock opened at $47.91 on Monday. The company has a debt-to-equity ratio of 10.32, a quick ratio of 4.19 and a current ratio of 4.19. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -4.47 and a beta of 1.82. Intercept Pharmaceuticals has a 1 year low of $44.50 and a 1 year high of $125.00. The firm’s 50 day moving average price is $78.84 and its two-hundred day moving average price is $88.09.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($2.86) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.94) by $0.08. The firm had revenue of $72.60 million for the quarter, compared to analyst estimates of $69.67 million. Intercept Pharmaceuticals had a negative net margin of 127.53% and a negative return on equity of 430.51%. The firm’s quarterly revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($3.03) earnings per share. As a group, equities analysts predict that Intercept Pharmaceuticals will post -11.3 EPS for the current fiscal year.
In other Intercept Pharmaceuticals news, Director Paolo Fundaro sold 595,578 shares of Intercept Pharmaceuticals stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $84.60, for a total transaction of $50,385,898.80. Following the completion of the sale, the director now owns 19,433 shares of the company’s stock, valued at approximately $1,644,031.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 595,817 shares of company stock valued at $50,405,516 in the last three months. Company insiders own 23.70% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Efficient Wealth Management LLC acquired a new stake in shares of Intercept Pharmaceuticals in the 1st quarter valued at $31,000. PNC Financial Services Group Inc. lifted its stake in shares of Intercept Pharmaceuticals by 42.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 790 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 234 shares during the last quarter. First Mercantile Trust Co. lifted its stake in shares of Intercept Pharmaceuticals by 17.5% in the 1st quarter. First Mercantile Trust Co. now owns 938 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 140 shares during the last quarter. Credit Agricole S A acquired a new stake in shares of Intercept Pharmaceuticals in the 1st quarter valued at $76,000. Finally, Sunbelt Securities Inc. acquired a new stake in shares of Intercept Pharmaceuticals in the 4th quarter valued at $41,823,000. 76.46% of the stock is owned by institutional investors and hedge funds.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Further Reading: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.